Results 191 to 200 of about 8,958 (210)
Some of the next articles are maybe not open access.
Immunomodulation in Oncolytic Measles Virotherapy
2019With the recognition of oncolytic virotherapy as an immunotherapy, the distinct interactions between oncolytic agents and the immune system have come into focus. The role of the immune system in oncolytic virotherapy is somewhat ambiguous: While preexisting or arising immunity directed against viral antigens may preclude efficient viral replication and
Laura, Dietz, Christine E, Engeland
openaire +2 more sources
Oncolytic Virotherapy of Cancer
2010It has been almost two decades since the first genetically engineered oncolytic virus was reported in 1991. Since then, many novel strategies have been developed to further improve oncolytic virus tumor selectivity and antitumoral potency, which are the two most important factors that would eventually determine the clinical safety and efficacy of any ...
Nanhai G. Chen, Aladar A. Szalay
openaire +1 more source
Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective
Cancer Cell, 2021Egle Ramelyte +2 more
exaly
Oncolytic Virotherapy in Breast Cancer
MedScienBreast cancer has a high incidence and fatality rate, making it a major worldwide health problem. Traditional treatment methods, treatments including chemotherapy, radiation therapy, and surgery, are partially effective in treating advanced breast cancer.
openaire +1 more source
Oncolytic Virotherapy for Malignant Gliomas
Journal of Clinical Oncology, 2018Peter A, Forsyth, Daniel, Abate-Daga
openaire +2 more sources
Promising OS with oncolytic virotherapy
Nature Reviews Clinical Oncology, 2022openaire +2 more sources
Oncolytic Virotherapy: A Contest between Apples and Oranges
Molecular Therapy, 2017Stephen J Russell, Kah-Whye Peng
exaly
Global dynamics of reaction-diffusion oncolytic M1 virotherapy with immune response
Applied Mathematics and Computation, 2020A M Elaiw
exaly
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Cell, 2017Antoni Ribas +2 more
exaly